{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-040388","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-10-21T20:15:17+00:00","discovered_at":"2026-10-21T20:18:16.396912+00:00","generated_at":"2026-10-21T20:18:56.840981+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA approves GSK/Ionis Hibsago (bepirovirsen) for chronic hepatitis B; Ionis earns 10-12% royalties","bullets":["FDA approved Hibsago (bepirovirsen) for CHB in adults without cirrhosis, on NrtI therapy ≥6 months, with suppressed HBV DNA and HBsAg ≤3000 IU/ml.","Phase 3 B-Well pooled data: 19% functional cure (233 of 1,220) vs 0 of 614 on placebo; 26% (200 of 768) in patients with HBsAg ≤1000 IU/ml.","Approval granted under FDA priority review and Breakthrough Therapy Designation; bepirovirsen is also approved in Japan, with more global decisions expected.","Ionis licensed bepirovirsen to GSK in 2019; already received upfront, license fee and milestone payments, and is eligible for more milestones plus 10-12% tiered royalties.","CHB affects roughly 1.7 million people in the U.S.; label carries boxed warnings for on-treatment hepatic flares and thrombocytopenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-040388","json":"https://secwatch.observer/filing/0001140361-26-040388.json","markdown":"https://secwatch.observer/filing/0001140361-26-040388.md","text":"https://secwatch.observer/filing/0001140361-26-040388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/0001140361-26-040388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-21T20:18:56.840981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}